Kuros Biosciences
-
Extremities
Kuros Biosciences Expands into Extremities Markets
Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the…
Read More » -
Top Stories
Foot Innovate Welcomes New Corporate Partner: Kuros Biosciences
October 9, 2024 – OrthoSpineNews – Foot Innovate is pleased to announce Kuros Biosciences as its newest corporate partner. Kuros…
Read More » -
Financial
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Press Release, March 13, 2024 – Kuros Biosciences – Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7…
Read More » -
Biologics
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for interbody use Kuros continues…
Read More » -
Biologics
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in a difficult-to-treat…
Read More » -
Biologics
Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
Rare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level…
Read More » -
Biologics
Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales
Ad hoc announcement pursuant to Article 53 of the SIX listing rules MagnetOs U.S. YTD sales increase 119% in 2021…
Read More » -
Biologics
Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
SCHLIEREN (ZURICH), Switzerland, March 02, 2021 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that it has signed sales…
Read More » -
Biologics
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH
SCHLIEREN (ZURICH), Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today announced…
Read More » -
Biologics
Kuros Biosciences Reports Results for First Half 2020
ZURICH, Switzerland, Aug. 12, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences, a leader in next generation bone graft technologies, today reported…
Read More » -
Biologics
Kuros Biosciences Further Strengthens Orthobiologics Patent Portfolio
SCHLIEREN (ZURICH), Switzerland, July 22, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced that its Dutch subsidiary, Kuros…
Read More » -
Biologics
Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading Synthetic Bone Grafts in Spinal Fusion
SCHLIEREN (ZURICH), Switzerland, Jan. 30, 2020 (GLOBE NEWSWIRE) — Kuros Biosciences (SIX: KURN) today announced the publication of data from…
Read More » -
Biologics
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion
Kuros to conduct Phase 2a trial in spinal fusion, comparing Fibrin-PTH to autograftPrimary endpoint is radiographic interbody fusion at 12 months SCHLIEREN…
Read More » -
Financial
Kuros Biosciences Reports Results for First Half 2019
Financial highlights CHF 13.4 million cash and cash equivalents (including trade and other receivables) at June 30, 2019Product sales were…
Read More » -
Biologics
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia and New Zealand
Kuros expands distribution of MagnetOs to Australia and New ZealandFirst sale of MagnetOs in Australia expected in 2020 SCHLIEREN (ZURICH),…
Read More »